Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 03, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg.".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 03, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Lamotrigine Extended-Release Tablets USP, 200 mg, 250 mg, and 300 mg.".